---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-222879"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2026-05-14T12:09:20+00:00"
generated_at: "2026-05-14T12:15:11.893068+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Benitec Q3 net loss $0.24/shr, cash $184.8M; BB-301 clinical progress continues

## Summary
- Net loss $11.9M ($0.24/shr) vs $14.5M ($0.38/shr) in prior year quarter; total expenses $13.6M.
- Cash and equivalents $184.8M, well-capitalized to advance BB-301 through pivotal study.
- Cohort 1 low-dose BB-301 shows durable responses at 12-24 months; Cohort 2 high dose safely treating patients.
- Oral presentation at ASGCT 2026 on May 15; FDA engagement mid-year to formalize pivotal study design.
- Updated BB-301 interim results expected 2H-2026; no treatment-related severe adverse events observed.

## SEC filing metadata
- accession: 0001193125-26-222879
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2026-05-14T12:09:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312526222879/0001193125-26-222879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312526222879/bntc-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-222879
- JSON: https://secwatch.observer/filing/0001193125-26-222879.json
- Plain text: https://secwatch.observer/filing/0001193125-26-222879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.